Page 366 - Binder2

They represent not just a new format, but a new
philosophy—one that Zea and Henry Daniell are putting
into clinical motion. And that’s why they’ve been largely
ignored by the incumbent industry.

Because this isn’t failure to innovate.
It’s a refusal to let go of a model that works for
shareholders—even if it stops working for patients.

Conclusion – The Disruption They Can’t Control

Big Pharma isn’t blind to innovation. It just knows how to
delay it. When a new therapeutic threatens to lower
margins, decentralize manufacturing, or bypass the
traditional gatekeepers, the industry doesn’t rush to
embrace it—it studies it, marginalizes it, or acquires it
before it spreads.

But edible biologics aren’t a molecule you can shelve or a
startup you can buy.
They’re a shift in logic.

They don’t improve the old system—they make it optional.
They don’t compete in the game—they change the board.

From lettuce-grown insulin to oral vaccines in rice, the
science is no longer speculative. It’s here. It’s been
validated in peer-reviewed studies and early clinical trials.
It works. And it solves problems that Pharma has never
been incentivized to fix—cost, access, tolerization,
stability.

What’s stopping it isn’t feasibility.
It’s the fortress.

364